Precautionary information, contraindications and baseline tests for bisphosphonates mentioned in this guideline are available in the product information (PI) on the Pharmaceutical Benefits Scheme website at www.pbs.gov.au
Recommendations for use of Bisphosphonates in early breast cancer was prepared and produced by:
Locked Bag 3 Strawberry Hills NSW 2012 Australia
Tel: +61 2 9357 9400 Fax: +61 2 9357 9477
© Cancer Australia 2011
This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from Cancer Australia to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Publications and Copyright contact officer, Cancer Australia, Locked Bag 3, Strawberry Hills NSW 2012.
Cancer Australia. Recommendations for use of bisphosphonates in early breast cancer. Cancer Australia, Surry Hills, NSW, 2011.
Cancer Australia does not accept any liability for any injury, loss or damage incurred by use of or reliance on the information. Cancer Australia develops material based on the best available evidence, however it cannot guarantee and assumes no legal liability or responsibility for the currency or completeness of the information.
* In July 2011, National Breast and Ovarian Cancer Centre (NBOCC) amalgamated with Cancer Australia to form a single national agency, Cancer Australia, to provide leadership in cancer control and improve outcomes for Australians affected by cancer.